GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 86 Essential Indicators 1. Percentage of capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total capex investments made by the entity. Details of improvements in environmental and social impacts • 100KW Solar panels installed for electricity generation as an extension to existing 500 KW Solar panels installed. • Implementation of Child Resistance and Senior Friendly Packaging caps for the bottles of selected product categories. • Removal of high noise DG set, ensuring generator area is free from mandated hearing protection, replacing with acoustic enclosure Genset. • Installation of site wide Public Address System and upgrading the assembly points for emergency response. • Upgradation of all safety related parts of control systems of identified high risk equipment to the machinery safety standards. • Installation of condition monitoring system on 1600 kVA transformer for online monitoring of parameters. • Completion of upgrades in the facility & effluent stream, achieving compliance to AMR requirements. • Improving the equipment capability & compliance on data integrity by upgrading equipment - Dissolution Media Degasser, Dissolution Tester, Sonicator, Microscope & Tablet Compression machines. • Deployment of platform for e-validation for equipment and facility, ensuring electronic generation, execution & approval of validation documents, migrating to a paperless process. • Deployment of Geo Segmentation, a Network Fire wall protection project to ensure cyber security controls in place. • Installation of Dehumidifier system for tablet testing in the QC Lab to meet controlled condition testing requirements. • Installation of New Dust Collection Units in the Ointment & Tablet facility, to improve controls on chemical exposure and mitigating risks. 2. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste. The packaging of the company’s products plays an important role in delivering safe, stable and trusted medicines and vaccines. However, the plastic used in product packaging has an impact on the environment. In alignment with our commitment to environmental sustainability, we complied with our Extended Producer Responsibility (EPR) obligation and collected back the equivalent amount of post-consumer plastic waste from the market and safely recycled and recovered it through authorised third parties. As per your company’s EPR commitments in FY 2021-22: 1,652.75 MT of plastic waste was collected and disposed in accordance with EPR. Your company’s processes to safely reclaim products for recusing, recycling and disposing of the end-of-life e-waste, hazardous waste and other waste are in alignment with the waste handling Rules of the Central Pollution Control Board and other applicable local laws and regulations. 3. Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No) . If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same Extended Producer Responsibility (EPR) is applicable to the entity’s activities. Your company complies with the EPR obligations put forth by the Central Pollution Control Board (CPCB) and disposes of all varieties of waste in an environmentally sustainable manner. As part of the company’s waste management processes, the waste has been segregated and handed over to government-approved vendors for recycling and incineration as appropriate. Leadership Indicators Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed of. Your company has a robust process in place to take back all its products that have expired or have suffered breakages. The products that are closer to their expiry dates or have expired are returned by the dealers/distributors to GSK’s distribution warehouse/ Clearing and Forwarding Agents. They are then sent for disposal via authorized waste management agencies for Business Responsibility and Sustainability Report